Preview

Rational Pharmacotherapy in Cardiology

Advanced search

INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2013-9-3-247-250

Full Text:

Abstract

Aim. To assess the risk factors of statin-associated muscle damage in patient with ischemic heart disease.
Material and methods. 258 patients with ischemic heart disease treated with statin were included into the study. Total plasma creatine kinase levels were measured and SLCO1B1*5 genotyping was performed. Relationship between statin therapy and adverse events was evaluated by Naranjo algorithm.
Results. Patients with muscle symptoms received statins significantly longer (48.8 vs 11.9 months, р<0.0001) and in higher doses, than patients without muscle pain/weakness. There were not significant differences in creatine kinase levels between patients with and without muscle symptoms. Patients with SLCO1B1*5 genotype were revealed in both groups, but more often (58%) among patients with muscle symptoms. Patients with abnormal C allele having muscle symptoms received statins significantly longer, than these without muscle signs (54.7 vs 13.9 months, р=0.0028).
Conclusion. Association between occurrence of muscle symptoms and SLCO1B1*5 allele carriership, statin dose and therapy duration was revealed. Creatine kinase examination was not valuable for finding of statin-induced muscle damage.

About the Authors

V. I. Petrov
Volgograd State Medical University, Volgograd
Russian Federation


O. N. Smuseva
Volgograd State Medical University, Volgograd
Russian Federation


Yu. V. Solovkina
Volgograd State Medical University, Volgograd
Russian Federation


References

1. Pugach I.M. Analysis of statin consumption in Russia in 2010–2011. Good Clinical Practice 2012; (2):56–62. Russian (Пугач И.М. Анализ потребления статинов в России в 2010–2011 году. Качественная Клиническая Практика 2012; (2):56–62).

2. Petrov V.I., Smuseva O.N., Solovkina Yu.V. Statin Safety. Bulletin VolgGMU 2012; 4(44): 9–14. Russian (Петров В.И., Смусева О.Н., Соловкина Ю.В. Безопасность статинов. Вестник ВолгГМУ 2012; 4(44):9–14).

3. Kameyama Y., Yamashita K., Kobayashi K. et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics 2005; 15: 513–22.

4. Niemi M., Schaeffeler E., Lang T. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429–40.

5. Pasanen M.K., Fredrikson H., Neuvonen P.J., Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726–33.

6. Pasanen M.K., Neuvonen M., Neuvonen P.J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics 2006; 16: 73–879.

7. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008; 359; 789–99.


For citation:


Petrov V.I., Smuseva O.N., Solovkina Y.V. INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2013;9(3):247-250. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-247-250

Views: 189


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)